成纤维细胞生长因子受体抑制剂相关的多灶性浆液性视网膜脱离：一例报告
Fibroblast Growth Factor Receptor Inhibitor-Associated Multifocal Serous Retinal Detachments: A Case Report.
作者信息
Kim Diana H, Xia Tian, Bracha Peter, VanderBeek Brian L
机构信息
Department of Ophthalmology, Scheie Eye Institute, Penn Presbyterian Medical Center, Philadelphia, PA, USA.
出版信息
J Vitreoretin Dis. 2021 May 19;6(4):337-340. doi: 10.1177/24741264211013629. eCollection 2022 Jul-Aug.
PURPOSE
This report aims to describe a case of bilateral, multifocal neurosensory retinal detachments that developed during erdafitinib therapy for metastatic urothelial carcinoma.
METHODS
A case report with color fundus imaging and spectral-domain optical coherence tomography imaging is presented.
RESULTS
A 50-year-old man with metastatic urothelial carcinoma had an unremarkable baseline ophthalmic examination prior to starting erdafitinib. At 3-month follow up, an examination revealed bilateral, multifocal retinal detachments. Because the patient was asymptomatic and erdafitinib was the only drug to which his tumor had responded, he was kept on the medication with close ophthalmic monitoring.
CONCLUSIONS
Erdafitinib, a fibroblast growth factor receptor inhibitor, can cause bilateral, multifocal retinal detachments. Continuation of erdafitinib may be considered in patients without significant visual impairment when the overall benefit of the medication appears to outweigh the risks.
目的
本报告旨在描述一例在使用厄达替尼治疗转移性尿路上皮癌期间发生的双侧、多灶性神经感觉性视网膜脱离病例。
方法
呈现一例伴有彩色眼底成像和光谱域光学相干断层扫描成像的病例报告。
结果
一名患有转移性尿路上皮癌的50岁男性在开始使用厄达替尼之前基线眼科检查无异常。在3个月的随访中，检查发现双侧多灶性视网膜脱离。由于患者无症状且厄达替尼是其肿瘤唯一有反应的药物，因此在密切眼科监测下继续用药。
结论
成纤维细胞生长因子受体抑制剂厄达替尼可导致双侧、多灶性视网膜脱离。当药物的总体获益似乎超过风险时，对于没有明显视力损害的患者可考虑继续使用厄达替尼。
Zotero 插件